Anticuerpos de unión a il-1beta para el uso en el tratamiento del cáncer
USO DE UN ANTICUERPO DE UNIÓN A IL-1Β O UN FRAGMENTO FUNCIONAL DEL ANTICUERPO, ESPECIALMENTE CANAKINUMAB O SU FRAGMENTO FUNCIONAL, O GEVOKIZUMAB O SU FRAGMENTO FUNCIONAL, Y BIOMARCADORES PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DEL CÁNCER CON UNA BASE INFLAMATORIA POR LO MENOS PARCIAL. Use of an IL-1β...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | THUREN, Tom RIDKER, Paul OTTEWELL, Penelope LIGUEROS-SAYLAN, Monica LAU, Yang Yi LIBBY, Peter DUGAN, Margaret MATCHABA, Patrice |
| description | USO DE UN ANTICUERPO DE UNIÓN A IL-1Β O UN FRAGMENTO FUNCIONAL DEL ANTICUERPO, ESPECIALMENTE CANAKINUMAB O SU FRAGMENTO FUNCIONAL, O GEVOKIZUMAB O SU FRAGMENTO FUNCIONAL, Y BIOMARCADORES PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DEL CÁNCER CON UNA BASE INFLAMATORIA POR LO MENOS PARCIAL.
Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CL2019003799A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CL2019003799A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CL2019003799A13</originalsourceid><addsrcrecordid>eNrjZPByzCvJTC5NLSrIL1ZISVUozcs8vDlPIVEhM0fXMCm1JFGhILEoUSE1R6G0OF8hNQ_EKilKLEnMzUzNK8kHaslRSD68MC85tYiHgTUtMac4lRdKczMou7mGOHvophbkx6cWFyQmp-allsQ7-xgZGFoaGBibW1o6GhoTpwoA8rQ19Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Anticuerpos de unión a il-1beta para el uso en el tratamiento del cáncer</title><source>esp@cenet</source><creator>THUREN, Tom ; RIDKER, Paul ; OTTEWELL, Penelope ; LIGUEROS-SAYLAN, Monica ; LAU, Yang Yi ; LIBBY, Peter ; DUGAN, Margaret ; MATCHABA, Patrice</creator><creatorcontrib>THUREN, Tom ; RIDKER, Paul ; OTTEWELL, Penelope ; LIGUEROS-SAYLAN, Monica ; LAU, Yang Yi ; LIBBY, Peter ; DUGAN, Margaret ; MATCHABA, Patrice</creatorcontrib><description>USO DE UN ANTICUERPO DE UNIÓN A IL-1Β O UN FRAGMENTO FUNCIONAL DEL ANTICUERPO, ESPECIALMENTE CANAKINUMAB O SU FRAGMENTO FUNCIONAL, O GEVOKIZUMAB O SU FRAGMENTO FUNCIONAL, Y BIOMARCADORES PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DEL CÁNCER CON UNA BASE INFLAMATORIA POR LO MENOS PARCIAL.
Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.</description><language>spa</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200731&DB=EPODOC&CC=CL&NR=2019003799A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200731&DB=EPODOC&CC=CL&NR=2019003799A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>THUREN, Tom</creatorcontrib><creatorcontrib>RIDKER, Paul</creatorcontrib><creatorcontrib>OTTEWELL, Penelope</creatorcontrib><creatorcontrib>LIGUEROS-SAYLAN, Monica</creatorcontrib><creatorcontrib>LAU, Yang Yi</creatorcontrib><creatorcontrib>LIBBY, Peter</creatorcontrib><creatorcontrib>DUGAN, Margaret</creatorcontrib><creatorcontrib>MATCHABA, Patrice</creatorcontrib><title>Anticuerpos de unión a il-1beta para el uso en el tratamiento del cáncer</title><description>USO DE UN ANTICUERPO DE UNIÓN A IL-1Β O UN FRAGMENTO FUNCIONAL DEL ANTICUERPO, ESPECIALMENTE CANAKINUMAB O SU FRAGMENTO FUNCIONAL, O GEVOKIZUMAB O SU FRAGMENTO FUNCIONAL, Y BIOMARCADORES PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DEL CÁNCER CON UNA BASE INFLAMATORIA POR LO MENOS PARCIAL.
Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPByzCvJTC5NLSrIL1ZISVUozcs8vDlPIVEhM0fXMCm1JFGhILEoUSE1R6G0OF8hNQ_EKilKLEnMzUzNK8kHaslRSD68MC85tYiHgTUtMac4lRdKczMou7mGOHvophbkx6cWFyQmp-allsQ7-xgZGFoaGBibW1o6GhoTpwoA8rQ19Q</recordid><startdate>20200731</startdate><enddate>20200731</enddate><creator>THUREN, Tom</creator><creator>RIDKER, Paul</creator><creator>OTTEWELL, Penelope</creator><creator>LIGUEROS-SAYLAN, Monica</creator><creator>LAU, Yang Yi</creator><creator>LIBBY, Peter</creator><creator>DUGAN, Margaret</creator><creator>MATCHABA, Patrice</creator><scope>EVB</scope></search><sort><creationdate>20200731</creationdate><title>Anticuerpos de unión a il-1beta para el uso en el tratamiento del cáncer</title><author>THUREN, Tom ; RIDKER, Paul ; OTTEWELL, Penelope ; LIGUEROS-SAYLAN, Monica ; LAU, Yang Yi ; LIBBY, Peter ; DUGAN, Margaret ; MATCHABA, Patrice</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CL2019003799A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2020</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>THUREN, Tom</creatorcontrib><creatorcontrib>RIDKER, Paul</creatorcontrib><creatorcontrib>OTTEWELL, Penelope</creatorcontrib><creatorcontrib>LIGUEROS-SAYLAN, Monica</creatorcontrib><creatorcontrib>LAU, Yang Yi</creatorcontrib><creatorcontrib>LIBBY, Peter</creatorcontrib><creatorcontrib>DUGAN, Margaret</creatorcontrib><creatorcontrib>MATCHABA, Patrice</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>THUREN, Tom</au><au>RIDKER, Paul</au><au>OTTEWELL, Penelope</au><au>LIGUEROS-SAYLAN, Monica</au><au>LAU, Yang Yi</au><au>LIBBY, Peter</au><au>DUGAN, Margaret</au><au>MATCHABA, Patrice</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Anticuerpos de unión a il-1beta para el uso en el tratamiento del cáncer</title><date>2020-07-31</date><risdate>2020</risdate><abstract>USO DE UN ANTICUERPO DE UNIÓN A IL-1Β O UN FRAGMENTO FUNCIONAL DEL ANTICUERPO, ESPECIALMENTE CANAKINUMAB O SU FRAGMENTO FUNCIONAL, O GEVOKIZUMAB O SU FRAGMENTO FUNCIONAL, Y BIOMARCADORES PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DEL CÁNCER CON UNA BASE INFLAMATORIA POR LO MENOS PARCIAL.
Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | spa |
| recordid | cdi_epo_espacenet_CL2019003799A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | Anticuerpos de unión a il-1beta para el uso en el tratamiento del cáncer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A18%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=THUREN,%20Tom&rft.date=2020-07-31&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECL2019003799A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |